Last updated: 11/07/2018 05:49:11

A Clinical Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of SRT501 in Subjects with Colorectal Cancer and Hepatic Metastases

Request patient level data
GSK study ID
113221
See study documents
Clinicaltrials.gov ID
NCT00920803
EudraCT ID
Not applicable
EU CT Number
Not applicable
Trial status
Completed
Completed
Overview
Eligibility
Locations
Study documents
Results summary
Plain language summaries
Additional information

Trial overview

Official title: A Phase 1, Double-Blind, Randomized Clinical Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of SRT501 in Subjects with Colorectal Cancer and Hepatic Metastases
Trial description: The primary purpose of this study is to determine the safety and tolerability of SRT501 (5.0 g) in subjects with colorectal cancer and hepatic metastases when administered once daily for 14 days.
The purpose is to also characterize the pharmacokinetic profile of SRT501 (5.0 g) by assessing levels of SRT501 and metabolites in blood, urine, bile and normal and malignant metastatic tissues in subjects with colorectal cancer and hepatic metastases when administered once daily for 14 days.
The secondary purpose is to examine the pharmacodynamics of SRT501 activity in both normal and malignant tissue samples, including blood and/or bodily fluids.
Primary purpose:
Basic Science
Trial design:
Parallel Assignment
Masking:
Triple (Participant, Care Provider, Investigator)
Allocation:
Randomized
Primary outcomes:

To determine the safety and tolerability of SRT501 when administered once daily for 14 days.

Timeframe: Safety will be continually assessed while subjects are on study.

To characterize the pharmacokinetic profile of SRT501 in blood and normal and malignant metastatic tissues when administered once daily for 14 days.

Timeframe: Pharmacokinetic samples will be obtained on Days 1, 2, 14, and 15.

Secondary outcomes:

To examine the pharmacodynamics of SRT501 activity in both normal and malignant tissue samples and blood.

Timeframe: Pharmacodynamic samples will be collected on Days 14 and 15 and will be analyzed at the end of the study.

Interventions:
Drug: Placebo
Drug: SRT501
Enrollment:
9
Observational study model:
Not applicable
Primary completion date:
Not applicable
Time perspective:
Not applicable
Clinical publications:
Lynne M. Howells1, D.P. Berry1, P.J. Elliott2, E.W. Jacobson2, E. Hoffmann2, B. Hegarty2, K. Brown1, W.P. Steward1, and A.J. Gescher1. Phase I Randomized, Double-Blind Pilot Study of Micronized Resveratrol (SRT501) in Patients with Hepatic Metastases— Safety, Pharmacokinetics, and Pharmacodynamics. [Cancer Prev Res (Phila Pa)]. 2011;4(9):1419-25.
Lynne M. Howells1, D.P. Berry1, P.J. Elliott2, E.W. Jacobson2, E. Hoffmann2, B. Hegarty2, K. Brown1, W.P. Steward1, and A.J. Gescher1. Phase I Randomized, Double-Blind Pilot Study of Micronized Resveratrol (SRT501) in Patients with Hepatic Metastases— Safety, Pharmacokinetics, and Pharmacodynamics. Cancer Prev Res (Phila Pa).2011;4(9):1419-25.
Medical condition
Neoplasms, Colorectal
Product
GR184072
Collaborators
GSK
Study date(s)
August 2008 to November 2009
Type
Interventional
Phase
1

Participation criteria

Sex
Female & Male
Age
18+ years
Accepts healthy volunteers
No
  • Be male or female greater than 18 years of age.
  • Have histologically or cytologically confirmed and diagnosed colorectal cancer with hepatic metastases.
  • Subject has a history / evidence of allergy or hypersensitivity to resveratrol.
  • Subject has had a major illness (other than colorectal cancer) in the past three months or any significant ongoing chronic medical illness that the Investigator would deem unfavorable for enrollment.
Inclusion and exclusion criteria
Inclusion criteria:
  • Be male or female greater than 18 years of age.
  • Have histologically or cytologically confirmed and diagnosed colorectal cancer with hepatic metastases.
  • Have not received chemotherapy or anti-neoplastic therapy for a malignancy within six weeks of first dose of SRT501 or placebo.
  • Have a life expectancy of greater than 3 months.
  • Voluntarily sign an Ethics Committee (EC)-approved informed consent form (ICF) to participate in the study after all relevant aspects of the study have been explained and discussed with the subject.
  • Be deemed, in the Investigator’s opinion, to be able to physically comply with SRT501 dosing.
  • Be amenable to surgical resection of the hepatic metastases.
  • Be clear of any history of HIV 1 and 2 and hepatitis B and C.
  • Have a normal 12-lead ECG or an ECG with abnormality considered to be clinically insignificant.
  • Have the ability to communicate with the investigative site staff in a manner sufficient to carry out all protocol procedures as described.
  • Female subject is either post-menopausal, surgically sterilized or be a woman of child bearing potential (WCBP) who has documented use of clinically prescribed hormonal contraceptives use consistently for three months prior to study entry. Females of child bearing potential, as well as their partners, must also use appropriate double-barrier birth control while participating in the study and for 28 days following the last dose of study drug. If a woman of child bearing potential has a surgically sterile partner, then that female is permitted to enroll if double-barrier birth control is practiced.
Exclusion criteria:
  • Subject has a history / evidence of allergy or hypersensitivity to resveratrol.
  • Subject has had a major illness (other than colorectal cancer) in the past three months or any significant ongoing chronic medical illness that the Investigator would deem unfavorable for enrollment.

    • Subject has inadequate organ function at the Screening visit as defined by the following laboratory values:

    • Platelet count ≤100,000 x 10^9/L
    • Hemoglobin ≤10.0 g/dL
    • Subjects with lower hemoglobin may be included at the Investigator’s discretion if the cause of anemia is due to bleeding from their tumor and post transfusion hemoglobin ≥10g/dL prior to dosing.
    • Absolute neutrophil count (ANC) ≤1500 x 10^6/L
    • Aspartate transaminase (AST) ≥2.5 x the upper limit of the normal range (ULN)
    • Alanine transaminase (ALT) ≥2.5 x ULN
    • Creatinine ≥ 140 umol/L
    • Albumin ≤3 g/dL
  • Subject has a history of or current gastro-intestinal diseases influencing drug absorption, with the exception of an appendectomy and/or colorectal cancer.
  • Subject has liver impairment as indicated by total bilirubin ≥2 x ULN, unless clearly related to the disease (ie, biliary occlusion due to tumor compression or confirmed Gilbert’s Disease as documented by the Investigator).
  • Subject had a myocardial infarction within 6 months prior to enrollment or has New York Hospital Association (NYHA) Class III or IV heart failure, uncontrolled angina, severe uncontrolled ventricular arrhythmias, or electrocardiographic evidence of acute ischemia or active conduction system abnormalities. Prior to study entry, any ECG abnormality at Screening has to be documented by the investigator as not medically relevant.
  • Excessive alcohol intake (more than UK recommended limit
  • 28 or 21 units per week for men or women respectively).
  • Subject has uncontrolled brain metastases or central nervous system disease.
  • Subject has participated in a clinical trial within the past three months.
  • Female subject is pregnant or breast-feeding. Confirmation that the subject is not pregnant must be established by a negative serum beta-hCG pregnancy test result obtained during the Screening period. Pregnancy testing is not required for post-menopausal or surgically sterilized women.

Trial location(s)

Location
Status
Contact us
Contact us
Location
GSK Investigational Site
Leicester, Leicestershire, United Kingdom, LE1 5WW
Status
Study Complete
Contact us

Study documents

Clinical study report
Available language(s): English
Download document(s)
Scientific result summary
Available language(s): English
Download document(s)

If you wish to request for full study report, please contact - [email protected]

Results overview

Refer to study documents

Recruitment status
Completed
Actual primary completion date
Not applicable
Actual study completion date
2009-11-11

Plain language summaries

Plain language summaries of clinical trial results for Phase 2-4 clinical trials that were initiated on or after January 2022 will be posted by GSK within one year following study completion.

Additional information about the trial

Participate in clinical trial
Additional information
Results for study 113221 can be found on the GSK Clinical Study Register.
Click here
Researchers can use this site to request access to anonymised patient level data and/or supporting documents from clinical studies to conduct further research.
Click here
Access to clinical trial data by researchers
Visit website